Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei

Nina Liu, Jason E. Cummings, Kathleen England, Richard A. Slayden, Peter J. Tonge

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives: As an initial step in developing novel antibacterials against Burkholderia pseudomallei, we have characterized the FabI enoyl-ACP reductase homologues in the type II fatty acid biosynthesis pathway from this organism and performed an initial enzyme inhibition study. Methods: A BLAST analysis identified two FabI enoyl-ACP reductase homologues, bpmFabI-1 and bpmFabI-2, in the B. pseudomallei genome, which were cloned, overexpressed in Escherichia coli and purified. Steady-state kinetics was used to determine the reaction mechanism and the sensitivity of bpmFabI-1 to four diphenyl ether FabI inhibitors. The antibacterial activity of the inhibitors was assessed using a wild-type strain of Burkholderia thailandensis (E264) and an efflux pump mutant (Bt38). Results: Consistent with its annotation as an enoyl-ACP reductase, bpmFabI-1 catalysed the NADH-dependent reduction of 2-trans-dodecenoyl-CoA via a sequential Bi Bi mechanism. In contrast, bpmFabI-2 was inactive with all substrates tested and only bpmfabI-1 was transcriptionally active under the growth conditions employed. The sensitivity of bpmFabI-1 to four diphenyl ethers was evaluated and in each case the compounds were slow-onset inhibitors with Ki values of 0.5-2 nM. In addition, triclosan and PT01 had MIC values of 30 and 70 mg/L for B. pseudomallei as well as a wild-type strain of B. thailandensis (E264), but MIC values of <1 mg/L for the efflux pump mutant Bt38. A reduction in MIC values was also observed for the pump mutant strain with the other diphenyl ethers. Conclusions: Provided that efflux can be circumvented, bpmFabI-1 is a suitable target for drug discovery.

Original languageEnglish (US)
Article numberdkq509
Pages (from-to)564-573
Number of pages10
JournalJournal of Antimicrobial Chemotherapy
Volume66
Issue number3
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Burkholderia pseudomallei
Phenyl Ethers
Oxidoreductases
Triclosan
Burkholderia
Drug Discovery
NAD
Fatty Acids
Genome
Escherichia coli
Enzymes
Growth

Keywords

  • B. pseudomallei
  • Efflux pumps
  • Slow-onset inhibition

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Liu, N., Cummings, J. E., England, K., Slayden, R. A., & Tonge, P. J. (2011). Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei. Journal of Antimicrobial Chemotherapy, 66(3), 564-573. [dkq509]. https://doi.org/10.1093/jac/dkq509

Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei. / Liu, Nina; Cummings, Jason E.; England, Kathleen; Slayden, Richard A.; Tonge, Peter J.

In: Journal of Antimicrobial Chemotherapy, Vol. 66, No. 3, dkq509, 03.2011, p. 564-573.

Research output: Contribution to journalArticle

Liu, N, Cummings, JE, England, K, Slayden, RA & Tonge, PJ 2011, 'Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei', Journal of Antimicrobial Chemotherapy, vol. 66, no. 3, dkq509, pp. 564-573. https://doi.org/10.1093/jac/dkq509
Liu, Nina ; Cummings, Jason E. ; England, Kathleen ; Slayden, Richard A. ; Tonge, Peter J. / Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei. In: Journal of Antimicrobial Chemotherapy. 2011 ; Vol. 66, No. 3. pp. 564-573.
@article{0e0f96c8d26f4d70a442772316ff9ccc,
title = "Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei",
abstract = "Objectives: As an initial step in developing novel antibacterials against Burkholderia pseudomallei, we have characterized the FabI enoyl-ACP reductase homologues in the type II fatty acid biosynthesis pathway from this organism and performed an initial enzyme inhibition study. Methods: A BLAST analysis identified two FabI enoyl-ACP reductase homologues, bpmFabI-1 and bpmFabI-2, in the B. pseudomallei genome, which were cloned, overexpressed in Escherichia coli and purified. Steady-state kinetics was used to determine the reaction mechanism and the sensitivity of bpmFabI-1 to four diphenyl ether FabI inhibitors. The antibacterial activity of the inhibitors was assessed using a wild-type strain of Burkholderia thailandensis (E264) and an efflux pump mutant (Bt38). Results: Consistent with its annotation as an enoyl-ACP reductase, bpmFabI-1 catalysed the NADH-dependent reduction of 2-trans-dodecenoyl-CoA via a sequential Bi Bi mechanism. In contrast, bpmFabI-2 was inactive with all substrates tested and only bpmfabI-1 was transcriptionally active under the growth conditions employed. The sensitivity of bpmFabI-1 to four diphenyl ethers was evaluated and in each case the compounds were slow-onset inhibitors with Ki values of 0.5-2 nM. In addition, triclosan and PT01 had MIC values of 30 and 70 mg/L for B. pseudomallei as well as a wild-type strain of B. thailandensis (E264), but MIC values of <1 mg/L for the efflux pump mutant Bt38. A reduction in MIC values was also observed for the pump mutant strain with the other diphenyl ethers. Conclusions: Provided that efflux can be circumvented, bpmFabI-1 is a suitable target for drug discovery.",
keywords = "B. pseudomallei, Efflux pumps, Slow-onset inhibition",
author = "Nina Liu and Cummings, {Jason E.} and Kathleen England and Slayden, {Richard A.} and Tonge, {Peter J.}",
year = "2011",
month = "3",
doi = "10.1093/jac/dkq509",
language = "English (US)",
volume = "66",
pages = "564--573",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei

AU - Liu, Nina

AU - Cummings, Jason E.

AU - England, Kathleen

AU - Slayden, Richard A.

AU - Tonge, Peter J.

PY - 2011/3

Y1 - 2011/3

N2 - Objectives: As an initial step in developing novel antibacterials against Burkholderia pseudomallei, we have characterized the FabI enoyl-ACP reductase homologues in the type II fatty acid biosynthesis pathway from this organism and performed an initial enzyme inhibition study. Methods: A BLAST analysis identified two FabI enoyl-ACP reductase homologues, bpmFabI-1 and bpmFabI-2, in the B. pseudomallei genome, which were cloned, overexpressed in Escherichia coli and purified. Steady-state kinetics was used to determine the reaction mechanism and the sensitivity of bpmFabI-1 to four diphenyl ether FabI inhibitors. The antibacterial activity of the inhibitors was assessed using a wild-type strain of Burkholderia thailandensis (E264) and an efflux pump mutant (Bt38). Results: Consistent with its annotation as an enoyl-ACP reductase, bpmFabI-1 catalysed the NADH-dependent reduction of 2-trans-dodecenoyl-CoA via a sequential Bi Bi mechanism. In contrast, bpmFabI-2 was inactive with all substrates tested and only bpmfabI-1 was transcriptionally active under the growth conditions employed. The sensitivity of bpmFabI-1 to four diphenyl ethers was evaluated and in each case the compounds were slow-onset inhibitors with Ki values of 0.5-2 nM. In addition, triclosan and PT01 had MIC values of 30 and 70 mg/L for B. pseudomallei as well as a wild-type strain of B. thailandensis (E264), but MIC values of <1 mg/L for the efflux pump mutant Bt38. A reduction in MIC values was also observed for the pump mutant strain with the other diphenyl ethers. Conclusions: Provided that efflux can be circumvented, bpmFabI-1 is a suitable target for drug discovery.

AB - Objectives: As an initial step in developing novel antibacterials against Burkholderia pseudomallei, we have characterized the FabI enoyl-ACP reductase homologues in the type II fatty acid biosynthesis pathway from this organism and performed an initial enzyme inhibition study. Methods: A BLAST analysis identified two FabI enoyl-ACP reductase homologues, bpmFabI-1 and bpmFabI-2, in the B. pseudomallei genome, which were cloned, overexpressed in Escherichia coli and purified. Steady-state kinetics was used to determine the reaction mechanism and the sensitivity of bpmFabI-1 to four diphenyl ether FabI inhibitors. The antibacterial activity of the inhibitors was assessed using a wild-type strain of Burkholderia thailandensis (E264) and an efflux pump mutant (Bt38). Results: Consistent with its annotation as an enoyl-ACP reductase, bpmFabI-1 catalysed the NADH-dependent reduction of 2-trans-dodecenoyl-CoA via a sequential Bi Bi mechanism. In contrast, bpmFabI-2 was inactive with all substrates tested and only bpmfabI-1 was transcriptionally active under the growth conditions employed. The sensitivity of bpmFabI-1 to four diphenyl ethers was evaluated and in each case the compounds were slow-onset inhibitors with Ki values of 0.5-2 nM. In addition, triclosan and PT01 had MIC values of 30 and 70 mg/L for B. pseudomallei as well as a wild-type strain of B. thailandensis (E264), but MIC values of <1 mg/L for the efflux pump mutant Bt38. A reduction in MIC values was also observed for the pump mutant strain with the other diphenyl ethers. Conclusions: Provided that efflux can be circumvented, bpmFabI-1 is a suitable target for drug discovery.

KW - B. pseudomallei

KW - Efflux pumps

KW - Slow-onset inhibition

UR - http://www.scopus.com/inward/record.url?scp=79951530324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951530324&partnerID=8YFLogxK

U2 - 10.1093/jac/dkq509

DO - 10.1093/jac/dkq509

M3 - Article

VL - 66

SP - 564

EP - 573

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 3

M1 - dkq509

ER -